Contact this trialFirst, we need to learn more about you.
Alkylating agents
CapTem + Y90 for Neuroendocrine Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing if a combination of two treatments is more effective than either treatment alone in preventing the progression of liver metastases in patients with neuroendocrine tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service